Literature DB >> 15296558

Delay in the diagnosis of testicular tumours - changes over the past 18 years.

Naveen S Vasudev1, Johnathan K Joffe, Carolyn Cooke, Fiona Richards, William G Jones.   

Abstract

BACKGROUND: Delay in the diagnosis of testicular cancer is associated with greater morbidity and poorer prognosis. While the national agenda relates to reducing time to referral and diagnostic delay, delay in presentation has previously been recognised as a major cause of delay in the diagnosis of this patient group. AIMS: To evaluate changes in referral times and patient awareness among men with testicular cancer in Yorkshire over the past 18 years. DESIGN OF STUDY: Prospective cohort study. Comparison was made with a similar study in Yorkshire in 1985.
SETTING: Leeds Cancer Centre Testicular Germ Cell Outpatient Clinic.
METHOD: Three hundred and thirty-one men, newly diagnosed with testicular cancer between August 1998 and October 2002, were asked to complete a questionnaire. The time taken from when the patient first noticed symptoms to their first visit to their general practitioner (GP), from their first GP visit to their first hospital visit, and from their first hospital visit to orchidectomy were recorded. We also asked patients about the treatment they were offered at their first GP visit.
RESULTS: Questionnaires were completed by 180 (54%) men. The median time that men took between when they first noticed symptoms and first visited their GP has decreased compared with 1985 (5 versus 2 weeks, respectively). No improvement was observed in referral times (mean = 3.55 versus 4.8 weeks). Ninety-one per cent of responders had heard of testicular cancer prior to diagnosis.
CONCLUSION: Patient performance has improved over the past 18 years. The data lends support to the effectiveness of national health education initiatives aimed at increasing public awareness and self-examination. GPs performed well in this study, assessing and referring men appropriately and urgently into secondary care.

Entities:  

Mesh:

Year:  2004        PMID: 15296558      PMCID: PMC1324839     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  8 in total

1.  Public awareness of testicular cancer and the value of self examination.

Authors:  J A Thornhill; R M Conroy; D G Kelly; A Walsh; J J Fennelly; J M Fitzpatrick
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-23

2.  Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours.

Authors: 
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

3.  Factors contributing to delay in diagnosis of testicular tumours.

Authors:  R T Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-02

4.  Delay in diagnosing testicular tumours.

Authors:  W G Jones; I Appleyard
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-25

5.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Patients' delay in the presentation of testis cancer in Ireland.

Authors:  J A Thornhill; J J Fennelly; D G Kelly; A Walsh; J M Fitzpatrick
Journal:  Br J Urol       Date:  1987-05

7.  Testicular cancer. Adolescent knowledge and attitudes.

Authors:  R M Vaz; D L Best; S W Davis
Journal:  J Adolesc Health Care       Date:  1988-11

8.  Qualitative study of men's perceptions of why treatment delays occur in the UK for those with testicular cancer.

Authors:  Alison Chapple; Sue Ziebland; Ann McPherson
Journal:  Br J Gen Pract       Date:  2004-01       Impact factor: 5.386

  8 in total
  10 in total

Review 1.  [Testis cancer: the UK as a model].

Authors:  S B Maddineni; N W Clarke
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

2.  Antidepressants and testicular cancer.

Authors:  Gary D Friedman; Joan Schwalbe; Ninah Achacoso; Maxwell V Meng; Candyce H Kroenke; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2013-11-26       Impact factor: 2.506

3.  Affluence and Private Health Insurance Influence Treatment and Survival in Non-Hodgkin's Lymphoma.

Authors:  Harry Comber; Marianna De Camargo Cancela; Trutz Haase; Howard Johnson; Linda Sharp; Jonathan Pratschke
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

4.  Knowledge and practice of testicular self-examination among secondary students at Ntare School in Mbarara District, South western Uganda.

Authors:  Catherine Atuhaire; Ambrose Byamukama; Rosaline Yumumkah Cumber; Samuel Nambile Cumber
Journal:  Pan Afr Med J       Date:  2019-06-06

Review 5.  Priorities in testis cancer care during Covid-19 Pandemic.

Authors:  Fernando P Secin
Journal:  Int Braz J Urol       Date:  2020-07       Impact factor: 1.541

6.  Testicular Cancer at the University of Port Harcourt Teaching Hospital: A 10-year Retrospective Review.

Authors:  V Abhulimen; E J Raphael
Journal:  J West Afr Coll Surg       Date:  2022-01-05

7.  Survival from testicular cancer in England and Wales up to 2001.

Authors:  R A Huddart
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

8.  Factors associated with testicular self-examination among unaffected men from multiple-case testicular cancer families.

Authors:  Susan T Vadaparampil; Richard P Moser; Jennifer Loud; June A Peters; Mark H Greene; Larissa Korde
Journal:  Hered Cancer Clin Pract       Date:  2009-05-29       Impact factor: 2.857

Review 9.  Optimal management of testicular cancer: from self-examination to treatment of advanced disease.

Authors:  Stephen Dw Beck
Journal:  Open Access J Urol       Date:  2010-08-12

10.  Delay in Diagnosis of Testicular Cancer; A Need for Awareness Programs.

Authors:  Çiğdem Öztürk; Joke Fleer; Harald J Hoekstra; Josette E H M Hoekstra-Weebers
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.